This report describes and explains the lung cancer liquid biopsy market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global lung cancer liquid biopsy market reached a value of nearly $1.11 billion in 2025, having grown at a compound annual growth rate (CAGR) of 25.3% since 2020. The market is expected to grow from $1.11 billion in 2025 to $3.12 billion in 2030 at a rate of 22.8%. The market is then expected to grow at a CAGR of 20.9% from 2030 and reach $8.07 billion in 2035.
Growth in the historic period resulted from increasing incidence of lung cancer, high prevalence of smoking and tobacco consumption, increasing prevalence of non-small cell lung cancer (NSCLC) and rise in investment in cancer diagnostics and research and development. Factors that negatively affected growth in the historic period were high cost of testing and limited clinical validation.
Going forward, rising demand for non-invasive and repeatable cancer testing, expansion of precision medicine and biomarker-driven oncology, favorable government initiatives towards lung cancer and increasing air pollution exposure will drive the growth. Factors that could hinder the growth of the lung cancer liquid biopsy market in the future include limited awareness and training among healthcare professionals, limited sensitivity in early-stage lung cancer detection and trade war and tariffs.
Market trends for the lung cancer liquid biopsy market include emphasis on deploying ultra-sensitive next-generation sequencing-based liquid biopsy technologies in large-scale clinical studies, strategic partnerships that integrate AI-powered care coordination with advanced genomic testing, developing AI-powered, decentralized diagnostic solutions and Industry 4.0 and intelligent manufacturing to enhance scalability, precision and efficiency in diagnostic production and deployment.
The lung cancer liquid biopsy market is segmented by product into instruments, consumables, kits and reagents, software and services. The instruments market was the largest segment of the lung cancer liquid biopsy market segmented by product, accounting for 48.8% or $545.7 million of the total in 2025. Going forward, the software and services segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by product, at a CAGR of 27.9% during 2025-2030.
The lung cancer liquid biopsy market is segmented by technology into multi-gene-parallel analysis (NGS) and single-gene analysis (PCR microarrays). The single-gene analysis (PCR microarrays) market was the largest segment of the lung cancer liquid biopsy market segmented by technology, accounting for 51.7% or $577.4 million of the total in 2025. Going forward, the multi-gene-parallel analysis (NGS) segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by technology, at a CAGR of 27.5% during 2025-2030.
The lung cancer liquid biopsy market is segmented by biomarker into cell-free deoxyribonucleic acid, circulating tumor deoxyribonucleic acid, extracellular vesicles, circulating tumor cells, other biomarkers. The circulating tumor deoxyribonucleic acid market was the largest segment of the lung cancer liquid biopsy market segmented by biomarker, accounting for 100% or $1.11 billion of the total in 2025. Going forward, the circulating tumor deoxyribonucleic acid segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by biomarker, at a CAGR of 19.9% during 2025-2030.
The lung cancer liquid biopsy market is segmented by clinical application into therapy selection, treatment monitoring, early cancer screening, recurrence monitoring and other applications. The therapy selection market was the largest segment of the lung cancer liquid biopsy market segmented by clinical application, accounting for 38.7% or $433 million of the total in 2025. Going forward, the therapy selection segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by clinical application, at a CAGR of 23.2% during 2025-2030.
The lung cancer liquid biopsy market is segmented by end user into diagnostics and imaging centers, hospitals, academics and research centers and other end users. The hospitals market was the largest segment of the lung cancer liquid biopsy market segmented by end user, accounting for 38.9% or $435.3 million of the total in 2025. Going forward, the academics and research centers segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by end user, at a CAGR of 25.5% during 2025-2030.
North America was the largest region in the lung cancer liquid biopsy market, accounting for 68% or $759.9 million of the total in 2025. It was followed by Western Europe, Asia-Pacific and then the other regions. Going forward, the fastest-growing regions in the lung cancer liquid biopsy market will be Africa and Middle East where growth will be at CAGRs of 45.9% and 40.1% respectively. These will be followed by Western Europe and Asia-Pacific where the markets are expected to grow at CAGRs of 30.2% and 28.5% respectively.
The global lung cancer liquid biopsy market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 28.08% of the total market in 2024. F. Hoffmann-La Roche Ltd. was the largest competitor with a 4.05% share of the market, followed by QIAGEN NV with 3.85%, Guardant Health Inc. with 3.61%, Thermo Fisher Scientific Inc. with 3.40%, Eurofins Scientific SE with 3.15%, NeoGenomics Laboratories Inc. with 2.42%, Agilent Technologies Inc. with 2.19%, Sysmex Corporation with 2.01%, Illumina Inc. with 1.75% and Biodesix Inc. with 1.65%.
The top opportunities in the lung cancer liquid biopsy market segmented by product will arise in the consumables, kits and reagents segment, which will gain $933.4 million of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by technology will arise in the multi-gene-parallel analysis (NGS) segment, which will gain $1.27 billion of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by biomarker will arise in the circulating tumor deoxyribonucleic acid segment, which will gain $1.64 billion of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by clinical application will arise in the therapy selection segment, which will gain $795 million of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by end user will arise in the hospitals segment, which will gain $723.9 million of global annual sales by 2030. The lung cancer liquid biopsy market size will gain the most in the USA at $941.4 million.
Player-adopted strategies in the lung cancer liquid biopsy market include focuses on enhancing its operational capabilities through new launches, enhancing its business operations through new developments and enhancing its geographical footprint across the globe through strategic partnerships.
Market-trend-based strategies for the lung cancer liquid biopsy market include focus on advancing circulating tumor DNA (ctDNA)-driven precision oncology solutions, enabling real-time treatment monitoring, adaptive immunotherapy strategies and improved patient stratification to enhance clinical outcomes and personalized cancer care, post-treatment monitoring and early detection of recurrence by leveraging multi-omics platforms and artificial intelligence and advancing early detection capabilities, improving analytical accuracy through multi-omics approaches, and integrating artificial intelligence to enhance clinical decision-making.
To take advantage of the opportunities, the analyst recommends the lung cancer liquid biopsy companies to focus on ctDNA-guided precision oncology expansion, focus on AI-driven recurrence monitoring solutions, focus on AI-enabled early detection platforms, focus on software and services expansion, focus on multi-gene NGS-based liquid biopsy platforms, focus on extracellular vesicle-based liquid biopsy development, expand in emerging markets, continue to focus on developed markets, focus on value-based and tiered pricing strategies, focus on clinical education and scientific evidence promotion, focus on digital outreach and patient awareness campaigns, focus on early cancer screening applications and focus on academic and research center partnerships.
This product will be delivered within 3-5 business days.
The global lung cancer liquid biopsy market reached a value of nearly $1.11 billion in 2025, having grown at a compound annual growth rate (CAGR) of 25.3% since 2020. The market is expected to grow from $1.11 billion in 2025 to $3.12 billion in 2030 at a rate of 22.8%. The market is then expected to grow at a CAGR of 20.9% from 2030 and reach $8.07 billion in 2035.
Growth in the historic period resulted from increasing incidence of lung cancer, high prevalence of smoking and tobacco consumption, increasing prevalence of non-small cell lung cancer (NSCLC) and rise in investment in cancer diagnostics and research and development. Factors that negatively affected growth in the historic period were high cost of testing and limited clinical validation.
Going forward, rising demand for non-invasive and repeatable cancer testing, expansion of precision medicine and biomarker-driven oncology, favorable government initiatives towards lung cancer and increasing air pollution exposure will drive the growth. Factors that could hinder the growth of the lung cancer liquid biopsy market in the future include limited awareness and training among healthcare professionals, limited sensitivity in early-stage lung cancer detection and trade war and tariffs.
Market trends for the lung cancer liquid biopsy market include emphasis on deploying ultra-sensitive next-generation sequencing-based liquid biopsy technologies in large-scale clinical studies, strategic partnerships that integrate AI-powered care coordination with advanced genomic testing, developing AI-powered, decentralized diagnostic solutions and Industry 4.0 and intelligent manufacturing to enhance scalability, precision and efficiency in diagnostic production and deployment.
The lung cancer liquid biopsy market is segmented by product into instruments, consumables, kits and reagents, software and services. The instruments market was the largest segment of the lung cancer liquid biopsy market segmented by product, accounting for 48.8% or $545.7 million of the total in 2025. Going forward, the software and services segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by product, at a CAGR of 27.9% during 2025-2030.
The lung cancer liquid biopsy market is segmented by technology into multi-gene-parallel analysis (NGS) and single-gene analysis (PCR microarrays). The single-gene analysis (PCR microarrays) market was the largest segment of the lung cancer liquid biopsy market segmented by technology, accounting for 51.7% or $577.4 million of the total in 2025. Going forward, the multi-gene-parallel analysis (NGS) segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by technology, at a CAGR of 27.5% during 2025-2030.
The lung cancer liquid biopsy market is segmented by biomarker into cell-free deoxyribonucleic acid, circulating tumor deoxyribonucleic acid, extracellular vesicles, circulating tumor cells, other biomarkers. The circulating tumor deoxyribonucleic acid market was the largest segment of the lung cancer liquid biopsy market segmented by biomarker, accounting for 100% or $1.11 billion of the total in 2025. Going forward, the circulating tumor deoxyribonucleic acid segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by biomarker, at a CAGR of 19.9% during 2025-2030.
The lung cancer liquid biopsy market is segmented by clinical application into therapy selection, treatment monitoring, early cancer screening, recurrence monitoring and other applications. The therapy selection market was the largest segment of the lung cancer liquid biopsy market segmented by clinical application, accounting for 38.7% or $433 million of the total in 2025. Going forward, the therapy selection segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by clinical application, at a CAGR of 23.2% during 2025-2030.
The lung cancer liquid biopsy market is segmented by end user into diagnostics and imaging centers, hospitals, academics and research centers and other end users. The hospitals market was the largest segment of the lung cancer liquid biopsy market segmented by end user, accounting for 38.9% or $435.3 million of the total in 2025. Going forward, the academics and research centers segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by end user, at a CAGR of 25.5% during 2025-2030.
North America was the largest region in the lung cancer liquid biopsy market, accounting for 68% or $759.9 million of the total in 2025. It was followed by Western Europe, Asia-Pacific and then the other regions. Going forward, the fastest-growing regions in the lung cancer liquid biopsy market will be Africa and Middle East where growth will be at CAGRs of 45.9% and 40.1% respectively. These will be followed by Western Europe and Asia-Pacific where the markets are expected to grow at CAGRs of 30.2% and 28.5% respectively.
The global lung cancer liquid biopsy market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 28.08% of the total market in 2024. F. Hoffmann-La Roche Ltd. was the largest competitor with a 4.05% share of the market, followed by QIAGEN NV with 3.85%, Guardant Health Inc. with 3.61%, Thermo Fisher Scientific Inc. with 3.40%, Eurofins Scientific SE with 3.15%, NeoGenomics Laboratories Inc. with 2.42%, Agilent Technologies Inc. with 2.19%, Sysmex Corporation with 2.01%, Illumina Inc. with 1.75% and Biodesix Inc. with 1.65%.
The top opportunities in the lung cancer liquid biopsy market segmented by product will arise in the consumables, kits and reagents segment, which will gain $933.4 million of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by technology will arise in the multi-gene-parallel analysis (NGS) segment, which will gain $1.27 billion of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by biomarker will arise in the circulating tumor deoxyribonucleic acid segment, which will gain $1.64 billion of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by clinical application will arise in the therapy selection segment, which will gain $795 million of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by end user will arise in the hospitals segment, which will gain $723.9 million of global annual sales by 2030. The lung cancer liquid biopsy market size will gain the most in the USA at $941.4 million.
Player-adopted strategies in the lung cancer liquid biopsy market include focuses on enhancing its operational capabilities through new launches, enhancing its business operations through new developments and enhancing its geographical footprint across the globe through strategic partnerships.
Market-trend-based strategies for the lung cancer liquid biopsy market include focus on advancing circulating tumor DNA (ctDNA)-driven precision oncology solutions, enabling real-time treatment monitoring, adaptive immunotherapy strategies and improved patient stratification to enhance clinical outcomes and personalized cancer care, post-treatment monitoring and early detection of recurrence by leveraging multi-omics platforms and artificial intelligence and advancing early detection capabilities, improving analytical accuracy through multi-omics approaches, and integrating artificial intelligence to enhance clinical decision-making.
To take advantage of the opportunities, the analyst recommends the lung cancer liquid biopsy companies to focus on ctDNA-guided precision oncology expansion, focus on AI-driven recurrence monitoring solutions, focus on AI-enabled early detection platforms, focus on software and services expansion, focus on multi-gene NGS-based liquid biopsy platforms, focus on extracellular vesicle-based liquid biopsy development, expand in emerging markets, continue to focus on developed markets, focus on value-based and tiered pricing strategies, focus on clinical education and scientific evidence promotion, focus on digital outreach and patient awareness campaigns, focus on early cancer screening applications and focus on academic and research center partnerships.
This product will be delivered within 3-5 business days.
Table of Contents
1 Executive Summary
6 Market Characteristics
8 Global Lung Cancer Liquid Biopsy Market Attractiveness Scoring And Analysis
9 Lung Cancer Liquid Biopsy Market, Supply Chain Analysis
10 Major Market Trends
11 Global Lung Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework
12 Global Lung Cancer Liquid Biopsy Market Size And Growth Analysis
13 Global Lung Cancer Liquid Biopsy Total Addressable Market (TAM) Analysis
14 Global Lung Cancer Liquid Biopsy Market Segmentation
15 Lung Cancer Liquid Biopsy Market, Regional and Country Analysis
16 Asia-Pacific Market
17 South East Asia Market
18 North America Market
19 Western Europe Market
20 South America Market
21 Eastern Europe Market
22 Middle East Market
23 Africa Market
24 Competitive Landscape And Company Profiles
25 Other Major And Innovative Companies
28 Lung Cancer Liquid Biopsy Market - Company Scoring Matrix
30 Key Mergers And Acquisitions
31 Recent Developments In Lung Cancer Liquid Biopsy
32 Opportunities And Strategies
33 Lung Cancer Liquid Biopsy Market, Conclusions And Recommendations
34 Appendix
Executive Summary
Lung Cancer Liquid Biopsy Global Market Opportunities And Strategies To 2035 provides the strategists; marketers and senior management with the critical information they need to assess the global lung cancer liquid biopsy market.Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Understand how the market is evolving with growth in the number of listed companies, greater focus on ESG and sustainability positioning, increased focus on broadening shareholder base and rising frequency of M&A and corporate restructuring.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for lung cancer liquid biopsy? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The lung cancer liquid biopsy market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider lung cancer liquid biopsy market; and compares it with other markets.
The report covers the following chapters:
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segments, key products, supply chain and market attractiveness scoring and analysis.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis And Strategic Analysis Framework - Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Global Market Size And Growth: Global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis: Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
- Market Segmentation: Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by product, by technology, by biomarker, by clinical application and by end user in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
- Regional Market Size And Growth: Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape: Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies: Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking: Briefs on the financials comparison between major players in the market.
- Competitive Dashboard: Briefs on competitive dashboard of major players.
- Key Mergers And Acquisitions: Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments: Information on recent developments in the market covered in the report.
- Market Opportunities And Strategies: Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations: This section includes recommendations for lung cancer liquid biopsy providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix: This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
1) By Product: Instruments; Consumables, Kits And Reagents; Software And Services
2) By Technology: Multi-Gene-Parallel Analysis (NGS); Single-Gene Analysis (PCR Microarrays)
3) By Biomarker: Circulating Tumor Deoxyribonucleic Acid; Extracellular Vesicles; Circulating Tumor Cells; Other Biomarkers
4) By Clinical Application: Therapy Selection; Treatment Monitoring; Early Cancer Screening; Recurrence Monitoring; Other Applications
5) By End User: Diagnostics And Imaging Centers; Hospitals; Academics And Research Centers; Other End Users
Companies Mentioned: F. Hoffmann-La Roche Ltd; QIAGEN NV; Guardant Health Inc; Thermo Fisher Scientific Inc; Eurofins Scientific SE
Countries: Australia; China; India; Indonesia; Japan; South Korea; USA; Canada; Mexico; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; lung cancer liquid biopsy indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- QIAGEN NV
- Guardant Health Inc
- Thermo Fisher Scientific Inc
- Eurofins Scientific SE
- NeoGenomics Laboratories Inc.
- Agilent Technologies Inc.
- Sysmex Corporation
- Illumina Inc.
- Biodesix Inc.
- Bio-Rad Laboratories
- Menarini Silicon Biosystems
- GRAIL
- IMBdx
- Lucence Diagnostics Pte Ltd
- Amoy Diagnostics Co., Ltd.
- Burning Rock Biotech Ltd
- Singlera Genomics
- HaploX
- Geneseeq Technology Inc
- Berry Oncology Co., Ltd
- Shenzhen Yucebio Technology Co., Ltd.
- Natera
- Foundation Medicine
- NYU Langone Health’s Perlmutter Cancer Center
- Datar Cancer Genetics
- Myriad Genetics Inc
- LungLife AI Inc
- Biodesix Inc
- Tempus
- OncoHelix
- Exact Sciences
- Menarini Silicon Biosystems Inc
- Inivata Ltd
- Sophia Genetics
